Analysis between Linagliptin and Azithromycin: In vitro and In vivo Interaction Study.

BACKGROUND Linagliptin is prescribed as a dipeptidyl peptidase-4 (DPP-4) inhibitor. Azithromycin is specified as an antibiotic that binds with 23s rRNA of the 50s ribosomal subunit obstructing the microbial protein synthesis. Our study focuses on the drug-drug interactions of these drugs. OBJECTIVE The purpose of the study is to understand the bioavailability and physicochemical approaches of Linagliptin and Azithromycin interaction mediated through the strength and nature of the complexation. METHODS The assessment drug interaction applying Ultraviolet-visible spectroscopy (UV/VIS), Ultra-Performance Liquid Chromatography (UPLC), Fourier transform infrared spectroscopy (FT-IR), and Differential scanning calorimetry (DSC) for In Vitro assessment. Also, Oral Glucose Tolerance Test (OGTT) in a mice model for In Vivo. RESULTS The mild variation observed at different pH at a specific temperature on Job's and Ardon's equation. On UPLC, the drug mixture is 2013793 and 54631 on 50 mg/l. The height of the drug mixture 579234 and 11442, respectively. The Azithromycin, the wavelength of 731.02 cm-1, 993.34 cm-1, 1379.10 cm-1, and 1718.58 cm-1 diminish from the mixture. Also, from Linagliptin, the wavelength of 1363.67 cm-1, 1473.62 cm-1, 1718.58 cm-1 declines from the drug mixture. The melting endotherm at 125.55°C of melting normalized energy of -3.0 W/mg and 225.75°C with melting normalized energy of -5.5 W/mg of the drug mixture on DSC. In the OGTT test, the blood glucose level decrease Linagliptin and the drug mixture at (13.58 %) and (57.25%). CONCLUSION Hence, the concomitant administration of Linagliptin and Azithromycin at a time might reduce the therapeutic effect of the formation of complexation.